Company intelligence / Profile preview

MorphoSys

Planegg/Munich/Martinsried, Bavaria, Germanymorphosis.com ↗

Ownership: Private
Development stage: Other

Overview

MorphoSys developed tafasitamab (marketed as Monjuvi in the US), approved by the FDA in July 2020 for use with lenalidomide to treat relapsed or refractory diffuse large B-cell lymphoma. The company also advanced pelabresib into late-stage clinical trials for myelofibrosis and tulmimetostat into clinical development for advanced cancers. MorphoSys has a history of successful partnerships and out-licensing programs.

Therapeutic areas: OncologyHematology
Modalities: Monoclonal antibodySmall moleculeProteinPeptides
Industry: Biotech

Partnerships

Incyte Corporation

Beyond the preview

Go deeper on MorphoSys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MorphoSys.

Explore the full profile